Seven months after separating into two companies, neurodegenerative disease specialist iPierian has agreed to be acquired by Bristol-Myers Squibb (BMS) for US$175 M in cash upfront plus potential milestone payments of up to US$550 M and royalties. With the acquisition, BMS will gain iPierian’s lead asset IPN007, a preclinical-stage antibody that targets the neurotoxic Tau protein and which is initially bring developed for progressive supranuclear palsy. For BMS, the deal is consistent with the company’s focus on genetically defined diseases and adds to its existing expertise in Tau biology.